Avro

About Avro

Avro Life Science is developing transdermal skin patches for the delivery of generic medications, specifically targeting therapeutic needs in pediatric and geriatric populations. This approach addresses the challenges of medication adherence and administration in these vulnerable age groups, enhancing treatment efficacy and patient compliance.

<problem> Administering oral medications to pediatric and geriatric patients presents significant challenges due to difficulties in swallowing, aversion to taste, and complex dosing regimens. Poor adherence to prescribed medication schedules in these populations leads to suboptimal therapeutic outcomes and increased healthcare costs. </problem> <solution> Avro Life Science is creating a portfolio of transdermal patches designed to deliver generic medications directly through the skin, bypassing the gastrointestinal tract and eliminating the need for oral administration. These patches offer a non-invasive, convenient alternative for delivering precise drug dosages over extended periods, improving patient compliance and reducing the risk of missed or incorrect doses. The technology aims to simplify medication management for caregivers and enhance the overall treatment experience for pediatric and geriatric patients. By focusing on established generic drugs, Avro Life Science seeks to provide cost-effective solutions that address unmet needs in vulnerable populations. </solution> <features> - Transdermal drug delivery system for sustained and controlled release of medication - Patch design optimized for pediatric and geriatric skin physiology - Formulation expertise to enhance drug permeation and bioavailability - Adhesion technology that ensures secure and comfortable patch application - Tamper-evident packaging to maintain drug integrity and prevent accidental exposure </features> <target_audience> The primary target audience includes pediatric patients, geriatric patients, their caregivers, and healthcare providers seeking improved medication adherence and simplified drug administration methods. </target_audience>

What does Avro do?

Avro Life Science is developing transdermal skin patches for the delivery of generic medications, specifically targeting therapeutic needs in pediatric and geriatric populations. This approach addresses the challenges of medication adherence and administration in these vulnerable age groups, enhancing treatment efficacy and patient compliance.

Where is Avro located?

Avro is based in Waterloo, Canada.

When was Avro founded?

Avro was founded in 2016.

How much funding has Avro raised?

Avro has raised $250.0K.

Who founded Avro?

Avro was founded by Andre Watson.

  • Andre Watson - Chairman/CEO
Location
Waterloo, Canada
Founded
2016
Funding
$250.0K
Employees
12 employees
Investors
AlphabridgeAlpha Bridge VenturesHeuristic CapitalUpHonest Capital
A

Avro

Avro Life Science is developing transdermal skin patches for the delivery of generic medications, specifically targeting therapeutic needs in pediatric and geriatric populations. This approach addresses the challenges of medication adherence and administration in these vulnerable age groups, enhancing treatment efficacy and patient compliance.

Waterloo, CanadaFounded 2016121K+ followers5/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.
Updated 3 months ago

Funding

$250.0K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Administering oral medications to pediatric and geriatric patients presents significant challenges due to difficulties in swallowing, aversion to taste, and complex dosing regimens. Poor adherence to prescribed medication schedules in these populations leads to suboptimal therapeutic outcomes and increased healthcare costs.

Solution

Avro Life Science is creating a portfolio of transdermal patches designed to deliver generic medications directly through the skin, bypassing the gastrointestinal tract and eliminating the need for oral administration. These patches offer a non-invasive, convenient alternative for delivering precise drug dosages over extended periods, improving patient compliance and reducing the risk of missed or incorrect doses. The technology aims to simplify medication management for caregivers and enhance the overall treatment experience for pediatric and geriatric patients. By focusing on established generic drugs, Avro Life Science seeks to provide cost-effective solutions that address unmet needs in vulnerable populations.

Target Audience

The primary target audience includes pediatric patients, geriatric patients, their caregivers, and healthcare providers seeking improved medication adherence and simplified drug administration methods.

Features

  • Transdermal drug delivery system for sustained and controlled release of medication
  • Patch design optimized for pediatric and geriatric skin physiology
  • Formulation expertise to enhance drug permeation and bioavailability
  • Adhesion technology that ensures secure and comfortable patch application
  • Tamper-evident packaging to maintain drug integrity and prevent accidental exposure
1
This profile is AI-generated and may contain inaccuracies.